Dynamk

Dynamk Capital is a New York-based venture capital firm that specializes in investing in early-stage companies within the life sciences sector, particularly focusing on life science industrials. Established in 2016, Dynamk Capital targets startups that develop critical tools, technologies, and services essential for the discovery, development, and manufacturing of life-saving therapies. The firm plays a pivotal role in advancing innovative solutions across the biopharma continuum, from drug discovery to development and production. Dynamk Capital's investment strategy is centered around providing both capital and strategic support to early-stage companies, helping them scale and succeed in a highly competitive and complex industry. The firm's portfolio includes a diverse range of companies, such as RoosterBio, which specializes in cell and exosome manufacturing, and Virica Biotech, which focuses on enhancing viral vector manufacturing for gene therapy. These investments reflect Dynamk's commitment to driving innovation in biomanufacturing and life sciences. The firm recently closed its inaugural life sciences fund at $65 million, marking a significant milestone in its mission to support groundbreaking life science ventures. Dynamk Capital continues to be an active player in the venture capital space, leveraging its industry expertise to identify and nurture companies that have the potential to make substantial contributions to healthcare and biopharmaceutical advancements.